Clinical Trial Update: A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update describing a study of BL-B01D1 in combination with Osimertinib versus Osimertinib alone as first-line treatment for EGFR-mutated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BL-B01D1
• Osimertinib (osimertinib)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING